Tags

Type your tag names separated by a space and hit enter

Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril.
Expert Rev Cardiovasc Ther 2005; 3(1):15-29ER

Abstract

Perindopril is a long-acting, once-daily lipophilic angiotensin-converting enzyme inhibitor with high tissue angiotensin-converting enzyme affinity, lowering angiotensin II and potentiating bradykinin. Its efficacy, safety and tolerability are well established in the treatment of hypertension and heart failure. Moreover, large morbidity-mortality trials, such as the EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) and Perindopril pROtection aGainst REcurrent Stroke Study (PROGRESS), have shown that antihypertensive treatment with perindopril reduces and prevents cardiovascular disease in a large range of patients with vascular diseases, whether hypertensive or not. Thus, the outcome of these and other trials support the concept of cardiovascular protective properties of angiotensin-converting enzyme inhibition with perindopril in addition to the obvious blood-pressure-lowering effect. Considering its properties and the gathered clinical evidence on efficacy and tolerability, perindopril fulfils the criteria of the latest guidelines for hypertension and cardiovascular disease management and should therefore be considered as a first-line antihypertensive agent, forming a consistent part of the comprehensive strategy against hypertension and related cardiovascular complications.

Authors+Show Affiliations

University of Ferrara, Department of Cardiology, Arcispedale S Anna, Corso Giovecca 203, 44100 Ferrara, Italy. fri@dns.unife.it

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

15723572

Citation

Ferrari, Roberto. "Angiotensin-converting Enzyme Inhibition in Cardiovascular Disease: Evidence With Perindopril." Expert Review of Cardiovascular Therapy, vol. 3, no. 1, 2005, pp. 15-29.
Ferrari R. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril. Expert Rev Cardiovasc Ther. 2005;3(1):15-29.
Ferrari, R. (2005). Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril. Expert Review of Cardiovascular Therapy, 3(1), pp. 15-29.
Ferrari R. Angiotensin-converting Enzyme Inhibition in Cardiovascular Disease: Evidence With Perindopril. Expert Rev Cardiovasc Ther. 2005;3(1):15-29. PubMed PMID: 15723572.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril. A1 - Ferrari,Roberto, PY - 2005/2/23/pubmed PY - 2005/5/10/medline PY - 2005/2/23/entrez SP - 15 EP - 29 JF - Expert review of cardiovascular therapy JO - Expert Rev Cardiovasc Ther VL - 3 IS - 1 N2 - Perindopril is a long-acting, once-daily lipophilic angiotensin-converting enzyme inhibitor with high tissue angiotensin-converting enzyme affinity, lowering angiotensin II and potentiating bradykinin. Its efficacy, safety and tolerability are well established in the treatment of hypertension and heart failure. Moreover, large morbidity-mortality trials, such as the EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) and Perindopril pROtection aGainst REcurrent Stroke Study (PROGRESS), have shown that antihypertensive treatment with perindopril reduces and prevents cardiovascular disease in a large range of patients with vascular diseases, whether hypertensive or not. Thus, the outcome of these and other trials support the concept of cardiovascular protective properties of angiotensin-converting enzyme inhibition with perindopril in addition to the obvious blood-pressure-lowering effect. Considering its properties and the gathered clinical evidence on efficacy and tolerability, perindopril fulfils the criteria of the latest guidelines for hypertension and cardiovascular disease management and should therefore be considered as a first-line antihypertensive agent, forming a consistent part of the comprehensive strategy against hypertension and related cardiovascular complications. SN - 1477-9072 UR - https://www.unboundmedicine.com/medline/citation/15723572/Angiotensin_converting_enzyme_inhibition_in_cardiovascular_disease:_evidence_with_perindopril_ L2 - http://www.tandfonline.com/doi/full/10.1586/14779072.3.1.15 DB - PRIME DP - Unbound Medicine ER -